NYSE:GKOSGlaukos Stock Price, Forecast & News

Glaukos' stock was trading at $38.64 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GKOS shares have increased by 22.3% and is now trading at $47.26.
View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 3 sell ratings, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Glaukos.

Glaukos is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Glaukos.

Glaukos will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Glaukos Corp (NYSE:GKOS) released its quarterly earnings data on Thursday, May, 7th. The medical instruments supplier reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.09. The medical instruments supplier earned $55.30 million during the quarter, compared to the consensus estimate of $55.05 million. Glaukos had a negative return on equity of 6.95% and a negative net margin of 15.65%. Glaukos's revenue for the quarter was up 2.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.04) earnings per share.
View Glaukos' earnings history.

10 brokers have issued 12-month target prices for Glaukos' stock. Their forecasts range from $34.00 to $67.00. On average, they expect Glaukos' share price to reach $47.22 in the next twelve months. This suggests that the stock has a possible downside of 0.1%.
View analysts' price targets for Glaukos.

Press coverage about GKOS stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Glaukos earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the next few days.
View the latest news about Glaukos.

Some companies that are related to Glaukos include Penumbra (PEN), Novocure (NVCR), Tandem Diabetes Care (TNDM), Hill-Rom (HRC), Globus Medical (GMED), Nevro (NVRO), Haemonetics (HAE), Integra Lifesciences (IART), ICU Medical (ICUI), Irhythm Technologies (IRTC), Inovio Pharmaceuticals (INO), NuVasive (NUVA), Inari Medical (NARI), Inspire Medical Systems (INSP) and Merit Medical Systems (MMSI).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include Alibaba Group (BABA), NVIDIA (NVDA), PTC Therapeutics (PTCT), Paypal (PYPL), Marvell Technology Group (MRVL), Boeing (BA), Micron Technology (MU), Shopify (SHOP), Baidu (BIDU) and Caterpillar (CAT).

(GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Glaukos' stock is owned by a number of institutional and retail investors. Top institutional investors include Interwest Venture Management Co. (1.46%), Rhenman & Partners Asset Management AB (0.32%), Calamos Advisors LLC (0.17%), Granite Investment Partners LLC (0.14%), Taylor Frigon Capital Management LLC (0.12%) and Comerica Bank (0.10%). Company insiders that own Glaukos stock include Chris M Calcaterra, Gilbert H Kliman, Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends for Glaukos.

GKOS stock was sold by a variety of institutional investors in the last quarter, including Interwest Venture Management Co., Rhenman & Partners Asset Management AB, Envestnet Asset Management Inc., UBS Group AG, Texas Permanent School Fund, Granite Investment Partners LLC, and Arizona State Retirement System. Company insiders that have sold Glaukos company stock in the last year include Joseph E Gilliam, and Thomas William Burns.
View insider buying and selling activity for Glaukos.

GKOS stock was bought by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, New York State Teachers Retirement System, Leap Investments LP, SG Americas Securities LLC, Everence Capital Management Inc., Mackay Shields LLC, Raymond James Financial Services Advisors Inc., and ProShare Advisors LLC.
View insider buying and selling activity for Glaukos.

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GKOS stock can currently be purchased for approximately $47.26.

Glaukos has a market capitalization of $2.09 billion and generates $236.98 million in revenue each year. The medical instruments supplier earns $15.42 million in net income (profit) each year or ($0.10) on an earnings per share basis. Glaukos employs 437 workers across the globe.

The official website for Glaukos is www.glaukos.com.

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]